Market Introduction
Middle East & Africa region consists of Saudi Arabia, South Africa, UAE and rest of MEA. Saudi Arabia is the largest market for blood brain barrier technologies market. Saudi Arabia's blood brain barrier technologies market is anticipated to witness a strong upsurge in the revenues during the forecast period on the back of growing healthcare awareness, rising neurodegenerative disorders. Greater awareness of health issues and increasing consumption of healthcare services sustain a substantial market for various therapies and treatments. Government of Saudi Arabia is working towards the betterment of population of the country. The improvement in the healthcare services, have increased in the last few years is from 5.9% of the government’s total budget in 2006 to 7.0% in 2014. In Saudi Arabia, increasing demand for healthcare and government initiatives favoring an increased participation from the private sector for the expansion in private sector and investors .
Countries such as UAE, and Saudi Arabia have also registered a significant number of positive patients. The COVID-19 pandemic has become the most significant challenge in the region. This challenge will be especially frightening for the region’s fragile and conflict-torn states—such as Iraq (1,963,264), Sudan (38,000), Iran (5,378,408), Israel (1,202,212) and Yemen (8,527) as it will lead to reduce imports due to disruptions in global trade, which further increases the shortages of medical supplies and other goods, resulting in a considerable price increase. The blood brain barrier technologies market in this pandemic is on rising, due to more of research about relation of blood brain barrier technologies with COVID-19 infection and its effect on the human body. Thus, pandemic has a positive impact on blood brain barrier technologies market.
Market Overview and Dynamics
The blood brain barrier technologies market in Middle East & Africa is expected to grow from US$ 196.72 million by 2028 from US$ 43.51 million in 2021. The market is estimated to grow at a CAGR of 24.1% from 2021 to 2028. Some neurologic disorders such as strokes, neuropathy, Alzheimer's disease, and Parkinson's disease are more common in the elderly, and their prevalence is increasing with higher life expectancies. According to the WHO, the population is aging rapidly worldwide. Between 2015 and 2050, the world's population over 60 years will nearly double, from 12% to 22%, and mental and neurological disorders among older adults are likely to account for 6.6% of the total disability-adjusted life year (DALYs) for this age group. Also, as per the same source, approximately 15% of adults aged 60 and over have a mental disorder. According to the CDC, Alzheimer's disease is the fifth leading cause of death in people 65 years and above. Also, the number of people living with Alzheimer's disease doubles every five years. Also the death rate due to neurological disorders is also increasing. For instance, according to the Alzheimer's Association, 1 in 3 seniors dies with Alzheimer's or dementia. Therefore, rising prevalence of age-associated neurological disorders increases the blood brain barrier technologies or better drug delivery. This factor is propelling the growth of the blood-brain barrier technologies market.
Key Market Segments
In terms of technology, the increasing permeability segment accounted for the largest share of the Middle East & Africa blood brain barrier technologies market in 2021. In terms of application, the parkinson’s disease segment accounted for the largest share of the Middle East & Africa blood brain barrier technologies market in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the blood brain barrier technologies market in Middle East & Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Bristol-Myers Squibb Company; Pfizer, Inc.; and Johnson & Johnson Services, Inc. among others.
Reasons to buy report
- To understand the Middle East & Africa blood brain barrier technologies market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Middle East & Africa blood brain barrier technologies market
- Efficiently plan M&A and partnership deals in Middle East & Africa blood brain barrier technologies market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Middle East & Africa blood brain barrier technologies market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Middle East & Africa region.
Middle East & Africa Blood Brain Barrier Technologies Market Segmentation
Middle East & Africa Blood Brain Barrier Technologies Market – By Technology
- Bispecific Antibody RMT Approach
- Trojan Horse Approach
- Increasing Permeability
- Passive Diffusion
- Other Non-Invasive BBB Technologies
Middle East & Africa Blood Brain Barrier Technologies Market – By Application
- Alzheimer’s Disease
- Epilepsy
- Parkinson’s Disease
- Multiple Sclerosis
- Hunter’s Syndrome
- Brain Cancer
- Others
Middle East & Africa Blood Brain Barrier Technologies Market – By Country
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
Middle East & Africa Blood Brain Barrier Technologies Market – Companies Mentioned
- Teva Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
Middle East & Africa Blood Brain Barrier Technologies Market Strategic Insights
Middle East & Africa Blood Brain Barrier Technologies Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$US$ 43.51 Million |
| Market Size by 2028 | US$ 196.72 Million |
| CAGR (2021 - 2028) | 24.1% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
Middle East & Africa Blood Brain Barrier Technologies Market Country and Regional Insights